Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19)

Plasma From Individuals Who Have Recovered From Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection as Treatment for Acute COVID-19 Disease

There is currently no effective treatment for COVID-19 except best supportive care. The aim is assess the safety, tolerability and efficacy of convalescent plasma for treatment of patients with varying degrees of COVID-19 illness.

Study Overview

• Status: Completed
• Conditions: COVID-19
• Intervention / Treatment: Biological: SARS-CoV-2 convalescent plasma

Detailed Description

Convalescent plasma has been shown to be safe and effective for treatment of several diseases. Preliminary data indicates that it is safe and effective for treatment of COVID-19. However, data is limited to small studies and case series on severely ill patients. The proposed study assesses the safety and efficacy earlier in the course of illness, in slightly less severe patients with the possibility of detecting less severe adverse events and the potential for early treatment to hinder the development of severe disease. Plasma is collected from consenting donors who have recovered from SARS-CoV-2.

• Study Type: Interventional
• Enrollment (Actual): 10
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• Sweden
  • Danderyd, Sweden, 182 57
    • Danderyd Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Age 18 and <81 years
• Active COVID-19 defined as symptoms + SARS CoV-2 identified from upper or lower airway samples
• Fever ≥38.5C, admitted to a study hospital, hypoxemia defined as having a peripheral oxygen saturation below 93% (measured by pulse oximetry) and a breathing rate of >20 breaths per minute without supplemental oxygen treatment
• A negative pregnancy test taken before inclusion and use of an acceptable effective method of contraception until treatment discontinuation if the participant is a woman of childbearing potential
• Written informed consent after meeting with a study physician and ability and willingness to complete follow up.

Exclusion Criteria:

• No matching plasma donor (exact matching in both the ABO system and the Rh system is required)
• Unavailability of plasma
• Significant growth of alternative lower airway pathogen such as Streptococcus pneumoniae or Haemophilus influenzae in sputum
• Disease duration >8 Days
• Estimated glomerular filtration rate <60 (kidney failure stage III or more)
• Pregnancy (urinary-hcg), breast feeding,
• History of severe allergic reactions
• Inability to give informed consent

• Significantly compromised immunity.*

  • Compromised immunity includes but is not limited to treatment with major immunosuppressive agents including high dose corticosteroids, anti-tumor necrosis factor (TNF) agents, calcineurin inhibitors, mTOR inhibitors, lymphocyte depleting biological agents, chemotherapeutic anti neoplastic agents. Also patients with advanced HIV/AIDS, severe immunodeficiency such as hypoglobulinemia, decompensated liver cirrhosis and bone marrow transplant the last year will be excluded.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

EXPERIMENTAL: Convalescent plasma treatment; All participants will receive a bag of convalescent plasma. The bag volume will be 180-200 ml. The first 10 patients will receive 1, 5, 10, 50 and 134 ml of plasma at 30 minute intervals while being closely monitored for adverse events, especially allergic reactions. The remaining twenty patients will receive the convalescent plasma as a slow infusion according to normal routines.

Biological: SARS-CoV-2 convalescent plasma; Treatment with convalescent plasma (180-200ml) from individuals who have recovered from SARS-CoV-2 infection

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Disease progression	Decrease in progression to requiring non-invasive or invasive ventilation	28 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adverse events (AE)	Adverse reactions and serious adverse reactions. The safety of the intervention will be assessed with regard to AEs, baseline medical conditions, and findings from the physical examination and laboratory tests. Possible adverse events will be elicited using a modification and Swedish translation (appendix 6) of Common Terminology Criteria for Adverse Events v5.0 and they will be continuously reported to the sponsor. Adverse events related to convalescent plasma therapy shall be followed to assess reversibility.	The reporting period for AEs starts at inclusion and ends at the final follow-up visit 2 months after inclusion.
Time ro resolution of fever and symptoms	Measured daily until discharged from the hospital.	Until discharged from the hospital, up to 2 months
Clearance of viraemia	SARS-CoV-2 RNA detection by polymerase chain reaction (PCR) in blood or serum. Blood samples for immunological analyses and serology will be taken daily until discharge, on day 28, and at 6 months.	Evaluated daily until discharge, at day 28, and last measurement taken at 6 months of follow-up after inclusion.
Inflammatory parameter C-reactive protein (CRP)	Time to normalization of inflammatory parameter C-reactive protein (CRP). Blood sample for this marker will be taken daily until normalized or discharged from hospital.	Until discharged from the hospital, up to 2 months
Inflammatory parameter white blood cell count	Time to normalization of inflammatory parameter white blood cell count (WBC). Blood sample for this marker will be taken daily until normalized or discharged from hospital.	Until discharged from the hospital, up to 2 months
Inflammatory parameter haemoglobin (Hb)	Time to normalization of inflammatory parameter haemoglobin (Hb). Blood sample for this marker will be taken daily until normalized or discharged from hospital.	Until discharged from the hospital, up to 2 months
Inflammatory parameter Pro-calcitonin	Time to normalization of inflammatory parameter Pro-calcitonin. Blood sample for this marker will be taken daily until normalized or discharged from hospital.	Until discharged from the hospital, up to 2 months
Inflammatory parameter Creatine Kinase	Time to normalization of inflammatory parameter Creatine Kinase. Blood sample for this marker will be taken daily until normalized or discharged from hospital.	Until discharged from the hospital, up to 2 months
Antibody response to SARS-CoV-2	Change in the antibody response to SARS-CoV-2 as measured in serum. Blood samples for immunological analyses and serology will be taken daily until discharge, on day 28, and at 6 months.	Evaluated daily until discharge, at day 28, and last measurement taken at 6 months of follow-up after inclusion.

Collaborators and Investigators

• Sponsor: Joakim Dillner
• Collaborators: Karolinska University Hospital; Karolinska Institutet; Danderyd Hospital
• Investigators: Principal Investigator: Johan Ursing, MD, PhD, Danderyd Hospital

Study record dates

Study Major Dates

• Study Start (ACTUAL): April 10, 2020
• Primary Completion (ACTUAL): June 30, 2020
• Study Completion (ACTUAL): December 31, 2020

Study Registration Dates

• First Submitted: April 10, 2020
• First Submitted That Met QC Criteria: May 13, 2020
• First Posted (ACTUAL): May 15, 2020

Study Record Updates

• Last Update Posted (ACTUAL): December 16, 2021
• Last Update Submitted That Met QC Criteria: December 1, 2021
• Last Verified: December 1, 2021

More Information

Terms related to this study

• Keywords: Safety; Effectiveness; SARS-CoV-2 infection; COVID-19 convalescent plasma treatment
• Additional Relevant MeSH Terms: Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; COVID-19
• Other Study ID Numbers: CP1

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: We will be sharing data but data the management plan is being designed.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No